Skip to Content Facebook Feature Image

Clarivate Reveals Top 100 Global Innovators 2025

Business

Clarivate Reveals Top 100 Global Innovators 2025
Business

Business

Clarivate Reveals Top 100 Global Innovators 2025

2025-03-12 16:00 Last Updated At:16:15

The Top 100 organizations generate $4.6 trillion USD in annual revenues, representing 4.4% of the global economy

LONDON, March 12, 2025 /PRNewswire/ -- Clarivate Plc (NYSE:CLVT), a leading global provider of transformative intelligence, today revealed its 2025 ranked list of Top 100 Global Innovators â€“ the organizations at the forefront of technology research and innovation worldwide.

The Top 100 organizations prioritize innovation as a central part of their business strategy. Their investment levels in science, engineering, product design and problem-solving is, on average, 8.8% of their revenues. Across the Top 100, this was almost $290 billion USD.

New this year: This year, Clarivate analyzes the convergence phenomenon – the integration of various scientific and engineering fields that promote the spread of innovation into products – through five macro-forces: sustainability, wellbeing, mobility, connectivity and automation. Within the top 0.5% of the most critical and valuable protected ideas, convergent inventions, those overlapping between innovation forces, account for almost 40%.

Geographical spread: Eleven countries and regions are identified in this year's list – one more than last year. Japan maintains its position as the biggest contributor to the Top 100 entities, with 33 organizations named, although it has seen a decrease of five since last year.  The United States has 18 organizations listed this year, Taiwan has 13, Germany and South Korea both have eight, France has seven, Mainland China has six, Switzerland has three, Netherlands has two, and Sweden and Finland, which is back on the list this year, both have one.

Industry sectors: There has been little change in the industry sector representation compared to 2024, with movements up and down by one or two individual representations. Four industry sectors saw an increase and five declined this year. Electronics and computing equipment continues to have the most Top 100 entities, followed by Semiconductors, Industrial systems, and Automotive.

Gordon Samson, President, Intellectual Property, Clarivate, said, "Being recognized as a Top 100 Global Innovator is a remarkable achievement given the pace of change - since 2000, we've seen an 80-fold increase in the volume of inventions. Competition is more global than ever before, and developments in one region can have a significant global impact. Hyperconnectivity and technological convergence play a pivotal role in driving innovation. The Top 100 organizations target innovation at the deployment and diffusion of technology and knowledge."

Other key findings from the 2025 report include:

  • Samsung Electronics maintains its position as the #1 ranked global innovator.
  • Six companies awarded Top 100 status for the first time: Samsung Electro-Mechanics, GE Aerospace, Siemens Energy, CATL, FORVIA and Caterpillar.
  • Six companies re-enter the Top 100: Nokia, NTT, Micron Technology, TE Connectivity, Quanta Computer and Asus.
  • 16 all-time recipient organizations retained Top 100 Global Innovator status: Samsung Electronics, Honda, Toyota, LG Electronics, Panasonic, Sony, Qualcomm, Toshiba, Hitachi, Ericsson, Dow, Fujitsu, Boeing, Shin-Etsu Chemical, Honeywell and NEC.

The Top 100 Global Innovators rankings are generated by the Clarivate Center for IP and Innovation Research.  Their analyses are underpinned by rigorous research leveraging the proprietary Derwent Strength Index, derived from the Derwent World Patents Index (DWPI) and global patent data to measure the influence of ideas, their success and rarity, and the investment in inventions.

To learn more, please visit our Top 100 Global Innovators 2025 site.

Detailed Methodology 
The Top 100 Global Innovators uses a complete comparative analysis of global invention data to assess the strength of every patented idea, using measures tied directly to their innovative power. To move from the individual strength of inventions to identifying the organizations that create them more consistently and frequently, Clarivate sets two threshold criteria that potential candidates must meet and then adds a measure of their patented innovation output over the past five years.

For full information, please visit our Top 100 Global Innovators 2025 methodology site.

About Clarivate Center for IP and Innovation Research
Combining more than 60 years of IP experience, the Clarivate Center for IP and Innovation Research empowers organizations worldwide to excel by providing expert guidance grounded in pioneering benchmarks and data-driven insights. Bringing together senior practitioners, consultants and data analysts, the Center performs research to establish and disseminate benchmarks that guide management and strategy. It works with legal, IP and innovation leaders to optimize IP operations and technology and improve IP decision-making, supported by industry-leading data, analytics and proven practices.

About Clarivate
Clarivate is a leading global provider of transformative intelligence. We offer enriched data, insights & analytics, workflow solutions and expert services in the areas of Academia & Government, Intellectual Property and Life Sciences & Healthcare. For more information, please visit www.clarivate.com

Media contact:
Sofia Nogués, Sr. External Communications Manager
newsroom@clarivate.com 

** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **

Clarivate Reveals Top 100 Global Innovators 2025

Clarivate Reveals Top 100 Global Innovators 2025

T. Rowe Price Investment Management, Inc. and Braidwell LP participate as new investors

Stephen Williams, MD, Ph.D. joins as Chief Scientific Officer

Rebecca Chambers and Frank Witney, Ph.D. appointed to Board of Directors

FREMONT, Calif., Jan. 12, 2026 /PRNewswire/ -- Alamar Biosciences, Inc. ("Alamar"), a leader in precision proteomics dedicated to advancing the early detection of disease, announced the close of an oversubscribed convertible notes financing, bringing in more than $50 million of new capital. Accounts advised by T. Rowe Price Investment Management, Inc. and Braidwell LP joined the financing as new investors. Existing investors, including Illumina Ventures and Sands Capital, also participated. The financing will support the continued commercial advancement of Alamar's precision proteomics platform.

"We deeply appreciate the continued support from our existing investors and are excited to welcome our new partners," said Dr. Yuling Luo, founder, chairman, and chief executive officer of Alamar. "Their confidence in our vision and strategy underscores the transformative potential of our work. This investment will enable us to accelerate innovation and continue to expand the reach of our platform, unlocking the full value of precision medicine and early disease detection."

Leadership and Board Expansion
Alamar also announced key additions to its executive leadership team and board of directors to support the company's continued growth and commitment to operational excellence.

 

 

To further strengthen its scientific leadership, Alamar welcomes Dr. Stephen Williams as Chief Scientific Officer. Steve brings more than three decades of experience in precision medicine and biomarker innovation. He most recently served as Chief Medical Officer at Standard BioTools and SomaLogic, and previously spent 18 years at Pfizer in senior leadership roles. A recognized leader in the scientific community, he has served on the NIH National Advisory Council for Biomedical Imaging and Bioengineering, helped launch the Alzheimer's Disease Neuroimaging Initiative, and co-founded the FDA-FNIH-PhRMA Biomarker Consortium.

Alamar has also appointed Rebecca Chambers and Dr. Frank Witney as directors to its board. Rebecca, Chief Financial Officer at Veracyte, brings deep financial and healthcare leadership experience from her current role as well as previous positions at Outset Medical, Illumina, Myriad Genetics and Life Technologies. Frank, an operating partner at Ampersand Capital Partners, adds over three decades of life sciences leadership experience, including serving as President and CEO of Affymetrix and Dionex Corporation, and currently sits on the boards of Revvity, Cerus Corporation, Standard BioTools, and several private companies.

"I am thrilled to welcome Steve to our leadership team, and Rebecca and Frank to our board of directors," said Dr. Yuling Luo. "Their deep expertise and diverse perspectives will be invaluable as we accelerate our mission to unleash the power of our Precision Proteomics platform, to enable broad impacts across health and disease. This is an exciting moment for Alamar, and we look forward to the impact their leadership will have on driving innovation and growth."

About Alamar Biosciences, Inc. 
Alamar Biosciences is a privately held life sciences company dedicated to powering precision proteomics to enable the earliest detection of disease. Leveraging its proprietary NULISA™ technology and the ARGO™ HT System, Alamar's platform is designed to deliver ultra-high sensitivity and addresses key limitations of existing technologies to deliver precision proteomics. For more information, please visit alamarbio.com

 

** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **

Alamar Biosciences Announces Close of Oversubscribed Convertible Notes Financing and Expansion of Leadership Team

Alamar Biosciences Announces Close of Oversubscribed Convertible Notes Financing and Expansion of Leadership Team

Alamar Biosciences Announces Close of Oversubscribed Convertible Notes Financing and Expansion of Leadership Team

Alamar Biosciences Announces Close of Oversubscribed Convertible Notes Financing and Expansion of Leadership Team

Alamar Biosciences Announces Close of Oversubscribed Convertible Notes Financing and Expansion of Leadership Team

Alamar Biosciences Announces Close of Oversubscribed Convertible Notes Financing and Expansion of Leadership Team

Alamar Biosciences Announces Close of Oversubscribed Convertible Notes Financing and Expansion of Leadership Team

Alamar Biosciences Announces Close of Oversubscribed Convertible Notes Financing and Expansion of Leadership Team

Recommended Articles